Moderna, Inc. (NASDAQ:MRNA) Receives $43.59 Average Target Price from Analysts

Key Points

• Moderna, Inc. has received a consensus recommendation of "Hold" from 24 analysts, with ratings varying from four 'sell' to one 'strong buy'.
• The average one-year target price for Moderna stocks among brokerages is $43.59, while the stock is currently priced at around $27.91.
• In its recent earnings report, Moderna posted an EPS of ($2.13), exceeding expectations while also experiencing a 41.1% decline in year-over-year revenue.

Moderna, Inc. (NASDAQ:MRNA - Get Free Report) has received a consensus recommendation of "Hold" from the twenty-four ratings firms that are covering the company, MarketBeat reports. Four equities research analysts have rated the stock with a sell recommendation, sixteen have issued a hold recommendation, three have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $42.8824.

Several equities research analysts have weighed in on MRNA shares. Cowen started coverage on Moderna in a report on Sunday, July 13th. They set a "hold" rating on the stock. Leerink Partners cut their price target on Moderna from $18.00 to $15.00 and set an "underperform" rating on the stock in a report on Friday. Evercore ISI set a $32.00 price target on Moderna in a report on Friday, August 1st. Bank of America cut their price target on Moderna from $26.00 to $25.00 and set an "underperform" rating on the stock in a report on Tuesday, July 22nd. Finally, William Blair restated a "market perform" rating on shares of Moderna in a report on Monday, June 2nd.

Moderna Trading Up 3.4%

MRNA traded up $0.90 during mid-day trading on Wednesday, hitting $27.12. 9,158,832 shares of the stock were exchanged, compared to its average volume of 8,387,155. The firm's fifty day moving average is $29.18 and its two-hundred day moving average is $29.05. Moderna has a 1-year low of $23.15 and a 1-year high of $84.28. The company has a market cap of $10.55 billion, a PE ratio of -3.60 and a beta of 1.83.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its quarterly earnings results on Friday, August 1st. The company reported ($2.13) earnings per share for the quarter, topping the consensus estimate of ($2.99) by $0.86. Moderna had a negative return on equity of 25.96% and a negative net margin of 94.31%.The company had revenue of $142.00 million for the quarter, compared to the consensus estimate of $116.26 million. During the same quarter in the prior year, the business earned ($3.33) EPS. Moderna's revenue was down 41.1% on a year-over-year basis. Moderna has set its FY 2025 guidance at EPS. As a group, research analysts anticipate that Moderna will post -9.61 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in MRNA. Norges Bank purchased a new position in shares of Moderna in the 2nd quarter valued at about $94,910,000. Federated Hermes Inc. lifted its position in shares of Moderna by 364.5% during the 2nd quarter. Federated Hermes Inc. now owns 2,869,271 shares of the company's stock worth $79,163,000 after buying an additional 2,251,497 shares during the last quarter. Voloridge Investment Management LLC lifted its position in shares of Moderna by 335.6% during the 4th quarter. Voloridge Investment Management LLC now owns 2,590,831 shares of the company's stock worth $107,727,000 after buying an additional 1,996,003 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Moderna by 19.1% during the 2nd quarter. Geode Capital Management LLC now owns 8,877,280 shares of the company's stock worth $244,458,000 after buying an additional 1,420,690 shares during the last quarter. Finally, Vanguard Group Inc. lifted its position in shares of Moderna by 3.2% during the 2nd quarter. Vanguard Group Inc. now owns 41,708,705 shares of the company's stock worth $1,150,743,000 after buying an additional 1,312,192 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company's stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.